Table 2

Reboxetine does not inhibit binding of [³H]MLA, [³H]cytisine, or [³H]epibatidine to rat whole brain membranes

Inhibitor	[³H]MLA	[³H]Cytisine	[³H]Epibatidine
MLA	0.64 ± 0.08 nM^2-a	567 ± 50 nM	2903 ± 244 nM
Nicotine	960 ± 125 nM	5.3 ± 1.0 nM	154 ± 14 nM
Cytisine	1370 ± 88 nM	1.1 ± 0.55 nM	44 ± 26 nM
Epibatidine	11 ± 0.7 nM	0.08 ± 0.01 nM	1.1 ± 0.08 nM
Reboxetine	4 ± 4%^2-b	0%	25%
Bupropion	3 ± 3%	8 ± 4%	10 ± 3%

n = 2–5 rats/group.

↵2-a Data areK_i values (mean ± S.E.M.).
↵2-b Data are the mean (±S.E.M.) of the percentage of inhibition of [³H]MLA binding at 100 μM reboxetine or bupropion, and the percentage of inhibition of [³H]cytisine and [³H]epibatidine binding at 1 μM reboxetine or bupropion.